Skip to main content

Table 4 Primary and secondary targets 12 weeks after treatment with rosuvastatin or rosuvastatin plus ezetimibe

From: Lipid lowering efficacy and safety of Ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients

  Primary Targets Secondary Targets
  LDL-C ≤2.0 mmol/L 50 % reduction in LDL ApoB ≤0.80 g/L non-HDL-C ≤2.6 TG <1.7 mmol/L ApoB:ApoA1 ratio <0.80 hsCRP <2 mg/L
Rosuvastatin 20 mg 2.07 19 % reduction 0.88 3.25 2.88 0.60 1.72
Rosuvastatin 10 mg + Ezetimibe 10 mg 2.12 24 % reduction 0.89 3.06 1.92 0.55 5.19
  1. LDL-C, low-density lipoprotein cholesterol; apoB, apolipoprotein B;; non-HDL-C, non- high-density lipoprotein cholesterol; TG, triglycerides; apoA1, apolipoprotein A1; hsCRP, high-sensitivity C-reactive protein